MXPA05001222A - Conjugados de compuestos de porfirina con agentes quimioterapeuticos. - Google Patents
Conjugados de compuestos de porfirina con agentes quimioterapeuticos.Info
- Publication number
- MXPA05001222A MXPA05001222A MXPA05001222A MXPA05001222A MXPA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A
- Authority
- MX
- Mexico
- Prior art keywords
- porphyrin
- compound according
- chemotherapeutic agent
- group
- doxorubicin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40051202P | 2002-08-02 | 2002-08-02 | |
| PCT/US2003/023898 WO2004012774A1 (en) | 2002-08-02 | 2003-07-30 | Conjugates of porphyrin compounds with chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05001222A true MXPA05001222A (es) | 2005-09-12 |
Family
ID=31495832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05001222A MXPA05001222A (es) | 2002-08-02 | 2003-07-30 | Conjugados de compuestos de porfirina con agentes quimioterapeuticos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040192665A1 (https=) |
| EP (1) | EP1525001A1 (https=) |
| JP (1) | JP2005539011A (https=) |
| AU (1) | AU2003257055A1 (https=) |
| CA (1) | CA2494214A1 (https=) |
| MX (1) | MXPA05001222A (https=) |
| WO (1) | WO2004012774A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7312244B2 (en) | 1999-04-30 | 2007-12-25 | Cellgate, Inc. | Polyamine analog-amino acid conjugates useful as anticancer agents |
| DE60029944T2 (de) * | 1999-04-30 | 2007-04-05 | Cellgate, Inc., Redwood City | Polyamine und ihre therapeutische verwendung |
| EP1515973A1 (en) * | 2002-06-26 | 2005-03-23 | Cellgate Inc. | Porphyrin-polyamine conjugates for cancer therapy |
| FR2867189A1 (fr) * | 2004-03-08 | 2005-09-09 | Ludovic Bourre | Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase |
| CA2573927A1 (en) | 2004-07-15 | 2006-01-19 | The University Of Sydney | Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis |
| EP2599497A3 (en) * | 2008-09-08 | 2013-09-25 | Hoffman/Barrett, L.L.C. | Porphyrazine-chemotherapeutic agents conjugates |
| JP6807831B2 (ja) | 2014-05-21 | 2021-01-06 | エントラーダ セラピューティクス，インコーポレイテッド | 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法 |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| WO2016033368A1 (en) | 2014-08-27 | 2016-03-03 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
| EP3471774A4 (en) | 2016-06-16 | 2020-04-15 | Oncoselect Therapeutics, LLC | PORPHYRINE COMPOUNDS AND COMPOSITIONS FOR TREATING CANCER |
| JP7372672B2 (ja) * | 2017-06-16 | 2023-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性医薬成分の複合体 |
| CA3078504A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
| WO2019148195A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of cal-pdz binding domain |
| WO2019165183A1 (en) | 2018-02-22 | 2019-08-29 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
| CN108409756B (zh) * | 2018-03-08 | 2019-12-10 | 莎穆(上海)生物科技有限公司 | 一种基于喜树碱类的异二聚体多功能前药及其制备方法和应用 |
| CN119504769B (zh) * | 2024-10-21 | 2025-09-30 | 高博药业有限公司 | 一种靶向her2的抗体偶联金（ⅲ）卟啉药物及其合成与肿瘤治疗应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435087A1 (de) * | 1994-09-30 | 1996-04-04 | Deutsches Krebsforsch | Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen |
| US5677350A (en) * | 1995-06-07 | 1997-10-14 | Wisconsin Alumni Research Foundation | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes |
| FR2764605B1 (fr) * | 1997-06-17 | 2004-03-26 | Univ Hyderabad | Molecules hybrides d'un photosensibilisateur et d'un agent chimiotherapeutique, leur procede de production et leur application collaterale en chimiotherapie et therapie photodynamique |
| US5889061A (en) * | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
| US20020155999A1 (en) * | 1998-04-30 | 2002-10-24 | Han In Suk | Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer |
| WO1999062551A1 (en) * | 1998-06-05 | 1999-12-09 | Board Of Regents, The University Of Texas System | Texaphyrin conjugates and uses thereof |
| DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
| US6482943B1 (en) * | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
| MXPA02003771A (es) * | 1999-10-15 | 2005-04-28 | Mayo Foundation | Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes anti-tumor. |
| CA2448570A1 (en) * | 2001-05-31 | 2002-12-05 | Miravant Pharmaceuticals, Inc. | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis |
| EP1515973A1 (en) * | 2002-06-26 | 2005-03-23 | Cellgate Inc. | Porphyrin-polyamine conjugates for cancer therapy |
-
2003
- 2003-07-25 US US10/627,211 patent/US20040192665A1/en not_active Abandoned
- 2003-07-30 WO PCT/US2003/023898 patent/WO2004012774A1/en not_active Ceased
- 2003-07-30 EP EP03766997A patent/EP1525001A1/en not_active Withdrawn
- 2003-07-30 JP JP2004526242A patent/JP2005539011A/ja active Pending
- 2003-07-30 CA CA002494214A patent/CA2494214A1/en not_active Abandoned
- 2003-07-30 MX MXPA05001222A patent/MXPA05001222A/es unknown
- 2003-07-30 AU AU2003257055A patent/AU2003257055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040192665A1 (en) | 2004-09-30 |
| EP1525001A1 (en) | 2005-04-27 |
| WO2004012774A1 (en) | 2004-02-12 |
| CA2494214A1 (en) | 2004-02-12 |
| AU2003257055A1 (en) | 2004-02-23 |
| JP2005539011A (ja) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05001222A (es) | Conjugados de compuestos de porfirina con agentes quimioterapeuticos. | |
| Renner et al. | Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy | |
| US20240042045A1 (en) | Nanoparticles containing multiple cleavable produgs for cancer therapy | |
| US6207660B1 (en) | Texaphyrin conjugates and uses thereof | |
| US20020049155A1 (en) | Cobalamin compounds useful as cardiovascular agents and as imaging agents | |
| EP3638367A1 (en) | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | |
| JP2001501596A (ja) | バイオコンジュゲートおよび生物学的活性剤の送達 | |
| US20050249663A1 (en) | Coadministration of transport protein with conjugated cobalamin to deliver agents | |
| ES2428088T3 (es) | Derivados de camptotecina como agentes quimioradiosensibilizadores | |
| CN112245591A (zh) | 化疗药物-低氧激活前药一体化前药自组装纳米粒的构建 | |
| US20040152687A1 (en) | Porphyrin-polyamine conjugates for cancer therapy | |
| CN1741801B (zh) | 水溶性阴离子型细菌叶绿素衍生物及其用途 | |
| US20230149546A1 (en) | Photosensitizer conjugated gold nanoparticles for radiotherapy enhancement | |
| CN118679145A (zh) | 用于递送药剂的生物分子-聚合物-药剂缀合物 | |
| CN113230417A (zh) | 葡萄糖和三苯基鏻修饰的脑肿瘤靶向脂质体的制备与应用 | |
| JP5372371B2 (ja) | カチオン性バクテリオクロロフィル誘導体及びその使用 | |
| US20040047917A1 (en) | Drug delivery and targeting with vitamin B12 conjugates | |
| US20090318370A1 (en) | Novel glycoconjugated chlorin derivatives and method of producing the same | |
| Verschuere et al. | Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7/8 agonist | |
| EP2216049A1 (en) | Drug conjugates with polyglycerols | |
| EP3442979A1 (en) | Topoisomerase poisons | |
| KR20250090018A (ko) | 면역항암제가 결합된 금속-유기 골격체를 포함하는 항암용 조성물 및 이의 용도 | |
| AU2002330153B2 (en) | Coadministration of transport protein with conjugated cobalamin to deliver agents | |
| AU2006201021A1 (en) | Cobalamin conjugates useful as imaging agents and as antitumor agents | |
| HK1081858B (en) | Water-soluble anionic bacteriochlorophyll derivatives and their uses |